J Korean Neuropsychiatr Assoc.  2022 Nov;61(4):267-273. 10.4306/jknpa.2022.61.4.267.

Korean Medication Algorithm Project for Bipolar Disorder 2022: Comorbid Physical Illnesses

Affiliations
  • 1Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
  • 2Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 3Department of Psychiatry, Naju National Hospital, Naju, Korea
  • 4Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea
  • 5Department of Psychiatry, Wonkwang University Hospital, Wonkwang University School of Medicine, Iksan, Korea
  • 6Department of Psychiatry, Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea
  • 7Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea
  • 8Department of Psychiatry, Soonchunhyang University Cheonan Hospital, College of Medicine, Soonchunhyang University, Cheonan, Korea
  • 9Department of Psychiatry, Chosun University Hospital, College of Medicine, Chosun University, Gwangju, Korea
  • 10Department of Psychiatry, Keyo Hospital, Uiwang, Korea
  • 11Department of Psychiatry, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, Korea

Abstract


Objectives
The present study was carried out to revise the guidelines for the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2018. The revision was carried out based on expert opinions to facilitate clinical decisions related to the treatment of bipolar disorders in patients with comorbid physical illnesses.
Methods
A 56-item questionnaire was developed; a consensus was arrived at by 87 out of 93 experts (93.5%), on the pharmacological treatment strategies to be used in cases of comorbid physical illnesses accompanying bipolar disorders.
Results
For patients with bipolar disorder exhibiting comorbid conditions, by consensus, lamotrigine, aripiprazole, and ziprasidone were recommended as the first-line strategies for metabolic syndrome; lamotrigine and aripiprazole were the recommended first-line strategies for cardiovascular problems; lithium and aripiprazole were the recommended first-line strategies for haptic problems; valproate, lamotrigine, aripiprazole, and quetiapine were the recommended first-line strategies for renal problems; and valproate and aripiprazole were the recommended first-line strategies for cerebrovascular problems or cerebral damage.
Conclusion
The present study is the most recent consensus among experts on recommendations for the treatment of bipolar disorders in patients with comorbid physical illnesses. Aripiprazole was recommended as the first-line pharmacotherapeutic agent in five comorbid physical conditions. This recommendation is similar to KMAP-BP 2018. Additionally, lamotrigine has been added as a first -line pharmacotherapeutic agent in patients with the metabolic syndrome, cardiovascular problems, and renal problems in the current algorithm.

Keyword

Bipolar disorder; Comorbid physical illnesses; Pharmacotherapy; KMAP-BP 2022
Full Text Links
  • JKNA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr